Fulcrum Therapeutics (FULC) has filed an S-1 amendment specifying its IPO of 4.5M common shares at maximum price of $18 per share, valuing the offering at $81M. Underwriters over-allotment will be an additional 675K shares.
On July 8, it filed a preliminary prospectus for a $93M offering.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.